Seizure resistance without parkinsonism in aged mice after tau reduction
about
Tau: The Center of a Signaling Nexus in Alzheimer's DiseaseAlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for Alzheimer disease.Unexpected role of interferon-γ in regulating neuronal connectivity and social behaviour.Motor and cognitive deficits in aged tau knockout mice in two background strains.Tau reduction diminishes spatial learning and memory deficits after mild repetitive traumatic brain injury in mice.Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction.No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin MiceThe Alzheimer's disease risk factor CD2AP maintains blood-brain barrier integrity.The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity.Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia.Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy.Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice.Antisense oligonucleotides: the next frontier for treatment of neurological disorders.Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis.Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models.
P2860
Q26768223-201952F7-7C26-4FD4-BB07-EF5C4FF2AE2CQ30009327-1657E9BE-1D99-4E0E-B6DC-CE2CB48F457DQ30354422-C479539C-C8B9-4150-875D-8C123588E11CQ34077327-52D939F6-1118-4377-9A0A-98C126B52364Q34796105-D7557947-AF18-447A-A8F0-87E53C2B869DQ35986968-9CAA7746-6D50-4E5E-A315-B5EE2F8CEB01Q36162472-60631449-ED6A-4E15-A9DA-4DB795676599Q36251986-174AA28B-1BA2-4524-809A-469956008559Q36759557-BEAA0FB8-5E04-4B8C-9E52-1DCBB7894A55Q38713424-7418B2E1-00EE-43D9-BF66-E899E9312721Q38853352-393370F6-7C8C-4569-95EA-04156DC169CCQ38998886-08806260-0E07-4B81-8CC5-2894EC9DC9D1Q46533399-E8CE1930-3F10-4248-AF78-BDF19465647FQ47344432-B22334AF-A5F7-4C5C-8A9E-CDE4492B4239Q47548337-26B77D50-4C7A-48D0-8E3D-D40CD0FF7909Q55385303-6A19A974-B933-4AE8-BA42-4367395329A9
P2860
Seizure resistance without parkinsonism in aged mice after tau reduction
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Seizure resistance without parkinsonism in aged mice after tau reduction
@ast
Seizure resistance without parkinsonism in aged mice after tau reduction
@en
type
label
Seizure resistance without parkinsonism in aged mice after tau reduction
@ast
Seizure resistance without parkinsonism in aged mice after tau reduction
@en
prefLabel
Seizure resistance without parkinsonism in aged mice after tau reduction
@ast
Seizure resistance without parkinsonism in aged mice after tau reduction
@en
P2093
P2860
P1476
Seizure resistance without parkinsonism in aged mice after tau reduction
@en
P2093
Alicia M Hall
Mark Kelinske
Zhiyong Li
P2860
P304
P356
10.1016/J.NEUROBIOLAGING.2014.05.001
P577
2014-05-09T00:00:00Z